Clinical Actionability News Today

The conventional way of classifying metastatic cancers according to their organ of origin is denying people access to drugs that could help them. The conventional way of classifying metastatic cancers according to their organ of origin is denying people access to drugs that could help them.

Tissue- and blood-based molecular analysis could help match patients with advanced hepatocellular carcinoma or hepatocholangiocarcinoma following disease progression on frontline atezolizumab and bevacizumab to targeted therapy or another TKI based on identified genomic alterations.

Patients with cancer are increasingly having tumor DNA sequenced to identify disease markers and potential targets, but some investigators question whether every cancer patient can benefit.

ESMO, the leading professional organization for medical oncology, today announced the launch of a new tool designed to make the renowned ESMO Clinical Practice Guidelines (CPGs) easier to use in oncologists' routine clinical practice and support optimal decision-making in a rapidly evolving medical field.

The availability of multi-gene tests was most inconsistent across 53 European countries, and reimbursement was seen as the greatest barrier.

Scientific advances are exciting, but not every discovery translates well into the clinic. Why is that? And how can companies successfully position...

The new definition factors in individual patients' outcomes, benefits to health systems, access to clinical trials, and shared decision making with patients.

SAFIR02-BREAST is a phase 2 trial that included 1462 patients with metastatic, HER2-negative breast cancer.

SAFIR02-BREAST is a phase 2 trial that included 1462 patients with metastatic, HER2-negative breast cancer.

PFS was better when targeted treatment for genomic alterations was supported by ESCAT criteria